Literature DB >> 27744279

Universal prescription drug coverage in Canada: Long-promised yet undelivered.

Steven G Morgan1, Katherine Boothe2.   

Abstract

Canada's universal public healthcare system is unique among developed countries insofar as it does not include universal coverage of prescription drugs. Universal, public coverage of prescription drugs has been recommended by major national commissions in Canada dating back to the 1960s. It has not, however, been implemented. In this article, we extend research on the failure of early proposals for universal drug coverage in Canada to explain failures of calls for reform over the past 20 years. We describe the confluence of barriers to reform stemming from Canadian policy institutions, ideas held by federal policy-makers, and electoral incentives for necessary reforms. Though universal "pharmacare" is once again on the policy agenda in Canada, arguably at higher levels of policy discourse than ever before, the frequently recommended option of universal, public coverage of prescription drugs remains unlikely to be implemented without political leadership necessary to overcome these policy barriers.
© 2016 The Canadian College of Health Leaders.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27744279      PMCID: PMC5094297          DOI: 10.1177/0840470416658907

Source DB:  PubMed          Journal:  Healthc Manage Forum        ISSN: 0840-4704


  34 in total

1.  Cost-related prescription nonadherence in the United States and Canada: a system-level comparison using the 2007 International Health Policy Survey in Seven Countries.

Authors:  Jae Kennedy; Steve Morgan
Journal:  Clin Ther       Date:  2009-01       Impact factor: 3.393

2.  Money left on the table: generic drug prices in Canada.

Authors:  Michael R Law
Journal:  Healthc Policy       Date:  2013-02

Review 3.  Going for the gold: the redistributive agenda behind market-based health care reform.

Authors:  R G Evans
Journal:  J Health Polit Policy Law       Date:  1997-04       Impact factor: 2.265

4.  Estimated cost of universal public coverage of prescription drugs in Canada.

Authors:  Steven G Morgan; Michael Law; Jamie R Daw; Liza Abraham; Danielle Martin
Journal:  CMAJ       Date:  2015-03-16       Impact factor: 8.262

Review 5.  Prescription drug insurance coverage and patient health outcomes: a systematic review.

Authors:  Aaron S Kesselheim; Krista F Huybrechts; Niteesh K Choudhry; Lisa A Fulchino; Danielle L Isaman; Mary K Kowal; Troyen A Brennan
Journal:  Am J Public Health       Date:  2015-02       Impact factor: 9.308

6.  Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications.

Authors:  Colin R Dormuth; Peter Neumann; Malcolm Maclure; Robert J Glynn; Sebastian Schneeweiss
Journal:  Med Care       Date:  2009-05       Impact factor: 2.983

7.  Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment.

Authors:  Sebastian Schneeweiss; Amanda R Patrick; Malcolm Maclure; Colin R Dormuth; Robert J Glynn
Journal:  Circulation       Date:  2007-04-09       Impact factor: 29.690

8.  Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.

Authors:  Steve Morgan; Gillian Hanley; Meghan McMahon; Morris Barer
Journal:  Healthc Policy       Date:  2007-08

Review 9.  A systematic review of cost-sharing strategies used within publicly-funded drug plans in member countries of the organisation for economic co-operation and development.

Authors:  Lianne Barnieh; Fiona Clement; Anthony Harris; Marja Blom; Cam Donaldson; Scott Klarenbach; Don Husereau; Diane Lorenzetti; Braden Manns
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

10.  Pan-Canadian overpricing of medicines: a 6-country study of cost control for generic medicines.

Authors:  Reed F Beall; Jason W Nickerson; Amir Attaran
Journal:  Open Med       Date:  2014-10-14
View more
  16 in total

1.  Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.

Authors:  Steven G Morgan; Winny Li; Brandon Yau; Nav Persaud
Journal:  CMAJ       Date:  2017-02-27       Impact factor: 8.262

2.  Inter- and intraprovincial inequities in public coverage of cancer drug programs across Canada: a plea for the establishment of a pan-Canadian pharmacare program.

Authors:  M Sorin; E L Franco; A Quesnel-Vallée
Journal:  Curr Oncol       Date:  2019-08-01       Impact factor: 3.677

3.  Prescription medication nonadherence associated with food insecurity: a population-based cross-sectional study.

Authors:  Fei Men; Craig Gundersen; Marcelo L Urquia; Valerie Tarasuk
Journal:  CMAJ Open       Date:  2019-09-23

4.  Contrasting current challenges from the Brazilian and Canadian national health systems: The Besrour Papers: a series on the state of family medicine in Canada and Brazil.

Authors:  David Ponka; Luiz Felipe Pinto; Molly Whalen-Browne; Anna Meuser; José Carlos Prado; Ophelia Michaelides; Katherine Rouleau
Journal:  Can Fam Physician       Date:  2019-12       Impact factor: 3.275

5.  The impact of OHIP+ pharmacare on use and costs of public drug plans among children and youth in Ontario: a time-series analysis.

Authors:  Benard N Miregwa; Anne Holbrook; Michael R Law; John N Lavis; Lehana Thabane; Lisa Dolovich; Michael G Wilson
Journal:  CMAJ Open       Date:  2022-09-27

6.  Cost-related nonadherence to prescription medications in Canada: a scoping review.

Authors:  Shikha Gupta; Mary Ann McColl; Sara J Guilcher; Karen Smith
Journal:  Patient Prefer Adherence       Date:  2018-09-06       Impact factor: 2.711

7.  Acceptability and feasibility of a national essential medicines list in Canada: a qualitative study of perceptions of decision-makers and policy stakeholders.

Authors:  Jordan D Jarvis; Adrianna Murphy; Pablo Perel; Nav Persaud
Journal:  CMAJ       Date:  2019-10-07       Impact factor: 8.262

Review 8.  Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare.

Authors:  Jaden Brandt; Brenna Shearer; Steven G Morgan
Journal:  J Pharm Policy Pract       Date:  2018-11-07

9.  Economic barriers, evidentiary gaps, and ethical conundrums: a qualitative study of physicians' challenges recommending HPV vaccination to older gay, bisexual, and other men who have sex with men.

Authors:  Daniel Grace; Mark Gaspar; Ron Rosenes; Ramandip Grewal; Ann N Burchell; Troy Grennan; Irving E Salit
Journal:  Int J Equity Health       Date:  2019-10-17

10.  Universal Pharmacare in Canada: A Prescription for Equity in Healthcare.

Authors:  Mohammad Hajizadeh; Sterling Edmonds
Journal:  Int J Health Policy Manag       Date:  2020-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.